We are live on ! Find out more
NMC

NEA Management Company Portfolio holdings

AUM $1.76B
1-Year Est. Return 223.33%
This Fund
S&P 500
This Quarter Est. Return
+18.27%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$1.57B
AUM Growth
+$53.2M
Cap. Flow
-$106M
Cap. Flow %
-6.75%
Top 10 Hldgs %
82.2%
Holding
38
New
3
Increased
3
Reduced
1
Closed
4

Top Buys

Rank Stock Value
1
SYBX
Synlogic
SYBX
+$18.8M
2
SBBP
Strongbridge Biopharma plc.
SBBP
+$15.4M
3
AVTX icon
Avalo Therapeutics
AVTX
+$2.27M
4
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$1.87M
5
AKTX
Akari Therapeutics
AKTX
+$1.75M

Top Sells

Rank Stock Value
1
SUPN icon
Supernus Pharmaceuticals
SUPN
+$107M
2
MM
MILLENNIAL MEDIA INC COM STK (DE)
MM
+$14.4M
3
TRVN
Trevena, Inc.
TRVN
+$10.7M
4
CVT
CVENT, INC.
CVT
+$8.22M
5
ECOM
CHANNELADVISOR CORPORATION
ECOM
+$5.53M

Sector Composition

Rank Sector Weight
1 Healthcare 72.28%
2 Communication Services 8.63%
3 Technology 7.87%
4 Consumer Discretionary 1.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSRO
1
DELISTED
TESARO, Inc.
TSRO
$463M 29.49%
8,854,255
– –
ARDX icon
2
Ardelyx
ARDX
$1.25B
$187M 11.87%
10,294,096
– –
GRPN icon
3
Groupon
GRPN
$1.06B
$136M 8.63%
2,208,648
– –
DERM
4
DELISTED
Dermira, Inc.
DERM
$121M 7.73%
3,506,649
– –
OPWR
5
DELISTED
OPOWER INC COM STK (DE)
OPWR
$95M 6.05%
8,997,290
– –
EPZM
6
DELISTED
Epizyme, Inc
EPZM
$82.5M 5.25%
5,149,740
– –
NVRO
7
DELISTED
NEVRO CORP.
NVRO
$67.1M 4.27%
993,428
– –
LOXO
8
DELISTED
Loxo Oncology, Inc
LOXO
$51M 3.25%
1,792,207
– –
CBIO
9
Crescent Biopharma
CBIO
$590M
$49.1M 3.13%
85,841
+90
+0.1% +$59.7K
TRVN
10
DELISTED
Trevena, Inc.
TRVN
$40M 2.55%
6,099
-1,600
-21% -$10.7M
CLVS
11
DELISTED
Clovis Oncology, Inc.
CLVS
$39.9M 2.54%
1,139,890
– –
LXRX icon
12
Lexicon Pharmaceuticals
LXRX
$1.03B
$31.7M 2.02%
2,382,286
– –
TRIV
13
DELISTED
TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK
TRIV
$26.2M 1.67%
3,945,191
– –
HIVE
14
DELISTED
Aerohive Networks
HIVE
$23.9M 1.52%
4,681,455
– –
CRCM
15
DELISTED
CARE.COM, INC.
CRCM
$23.3M 1.49%
3,260,989
– –
SYBX
16
DELISTED
Synlogic
SYBX
$18.6M 1.18%
+28,332
New +$18.8M
TCON
17
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$17.5M 1.11%
9,448
– –
SBBP
18
DELISTED
Strongbridge Biopharma plc.
SBBP
$16.3M 1.04%
+2,141,308
New +$15.4M
EXEL icon
19
Exelixis
EXEL
$14.1B
$12.4M 0.79%
2,207,000
– –
RIGL icon
20
Rigel Pharmaceuticals
RIGL
$715M
$9.83M 0.63%
324,315
– –
VIRX
21
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$7.01M 0.45%
37,094
+10,000
+37% +$1.87M
ORKA
22
Oruka Therapeutics
ORKA
$5.32B
$6.79M 0.43%
6,760
– –
OREX
23
DELISTED
Orexigen Therapeutics, Inc.
OREX
$6.38M 0.41%
370,900
– –
AUPH icon
24
Aurinia Pharmaceuticals
AUPH
$1.93B
$6.29M 0.4%
2,546,843
– –
CSBR icon
25
Champions Oncology
CSBR
$75.2M
$5.58M 0.36%
1,562,500
– –
1
2

Similar funds

NM
NWI Management New York $1.76B AUM 45.08% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.76B AUM 19.57% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.76B AUM 13.06% 1-Year Est. Return
SW
Simplicity Wealth Summit, New Jersey $1.76B AUM 20.49% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
PWP
Principle Wealth Partners Madison, Connecticut $1.75B AUM 21.63% 1-Year Est. Return
CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
KOCAA
Knights of Columbus Asset Advisors New Haven, Connecticut $1.77B AUM 31.28% 1-Year Est. Return

NEA Management Company's Q4 2015 Portfolio in Review

As of Q4 2015, NEA Management Company held 38 positions worth $1.57B, up 3.5% from $1.52B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

NEA Management Company withdrew a net $106M in Q4 2015, closing 4 positions and reducing 1 holding. Its most notable exit was Supernus Pharmaceuticals, an estimated $107M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, down from 73% a quarter earlier, followed by Communication Services and Technology.

Against the trend, NEA Management Company opened a new position in Synlogic worth $18.6M.

  • NEA Management Company's largest Q4 2015 buy was Synlogic: 28,332 shares worth $18.6M.
  • NEA Management Company added most to Viracta Therapeutics, Inc. Common Stock in Q4 2015, an estimated $1.87M increase.
  • NEA Management Company's biggest Q4 2015 reduction was Trevena, Inc., cutting an estimated $10.7M.
  • NEA Management Company fully exited Supernus Pharmaceuticals in Q4 2015, selling an estimated $107M.
  • NEA Management Company's ten largest holdings make up 82% of its $1.57B portfolio in Q4 2015.
  • NEA Management Company opened 3 new positions and closed 4 in Q4 2015.
  • NEA Management Company's portfolio value rose 3.5% quarter-over-quarter to $1.57B.

Based on NEA Management Company's 13F filing for Q4 2015, filed 22 Jan 2016.